HPS Pharmacies wish to advise that Bristol-Myers Squibb is anticipating a supply interruption for Orencia® as follows:
Orencia® ClickJect®
Abatacept 125mg
ARTG 236039
Orencia® Prefilled Syringe
Abatacept 125mg
ARTG 206764
Manufacturing issues are expected to impact supplies of Orencia® ClickJect® from early June to end-August 2024. Orencia® prefilled syringes are expected to be in short supply from mid-June to end-September 2024 due to increased demand.
Bristol-Myers Squibb is working to control the supply of these products. The Therapeutic Goods Administration (TGA) is also investigating strategies to minimise patient impact, which may include the creation of a Serious Scarcity Substitution Instrument (SSSI). Further information is available on the TGA website.
These supply issues only affect the subcutaneous presentation of Orencia®. Bristol-Myers Squibb advises that there is sufficient stock of Orencia® 250mg vials for intravenous infusion to support patients currently receiving it.
Retain this notice in a prominent position, including in other related business units until supplies return to normal. Report any problems identified with medicines, vaccines or medical devices to the TGA.
Should you require further information regarding this matter, please contact Bristol-Myers Squibb on 1800 067 567, or your pharmacist at HPS Pharmacies.
Subscribe Knowledge Centre Updates
Enter your details to receive Knowledge Centre updates